Center orders 11 mn doses of Covishield. Govt. says it will pay for priority group


  • Prime Minister announced Centre would bear the cost for vaccinating the priority group of three crore healthcare and frontline workers.
  • Central government placed a purchase order with the Punebased Serum Institute of India (SII) for 11 million doses of Oxford COVID19 vaccine, Covishield, at a cost of Rs.210 per dose. 
  • Recently, GoI approved COVISHIELD and COVAXIN for restricted use in emergency situation against Covid-19 in India.
  • The vaccines have been approved for use despite the companies not having completed clinical trials.




  • Developed by the Oxford University in association with Swedish-British drug company AstraZeneca.
  • Based on adenovirus found in chimpanzees (a weakened version of a common cold virus)
  • It has the genetic material of the SARS-CoV-2 spike protein 
  • Human immune system is expected to recognise this protein as a threat, and start building antibodies to resist it.
  • Serum Institute of India (SII) will be manufacturing it in India.


COVAXIN: India’s indigenous vaccine.

  • Developed by Bharat Biotech, Hyderabad along with the ICMR’s National Institute of Virology, Pune
  • Inactivated vaccine: which is developed by inactivating (killing) the live microorganisms that cause the disease.
  • This destroys the ability of the pathogen to replicate, but keeps it intact so that the immune system can still recognise it and produce an immune response.
  • It is expected to target more than just the spike protein.
  • It also aims to develop an immune response to the nucleocapsid protein (the shell of the virus that encloses its genetic material).
  • This vaccine is still under "clinical trial mode." Covaxin Phase-3 efficacy data is still not released.



  • COVAXIN is expected to be effective against latest variants of corona virus, including the UK variant, since it contains immunogens (epitopes) from other apart from Spike protein.
  • Immunogen is a stimulus that creates a humoral or cell-mediated immune response, whereas antigens are any substance that binds specifically to an antibody.



  • This user friendly mobile app for recording vaccine data is working as a beneficiary management platform having various modules.
  • The platform will be used for recording vaccine data and will form a database of healthcare workers too.
  • The app will have separate modules for administrator, registration, vaccination, beneficiary acknowledgement and reports.
  • Once people start to register for the app, the platform will upload bulk data on co-morbidity provided by local authorities.
  • In the process of forming database of Healthcare Workers, which is in an advanced stage across all States/UTs, data is presently being uploaded on the Co-WIN platform.


Prioritized Population Groups:

  • Healthcare Workers in both Government and Private Healthcare facilities
  • Frontline Workers including personnel from state and central police department, armed forces, home guard, civil defence organizations, disaster management volunteers and municipal workers and
  • Prioritized Age Group, which includes those aged above 50 years & those with co-morbidities
Print Friendly and PDF
blog comments powered by Disqus